The 3rd Webinar in COVID-19 Series: COVID-19 Treatment

COVID-19 Treatment

The 3rd Webinar in the COVID-19 series:  “COVID-19 Treatment” was held on Saturday, 4 December 2021, from 07.00 to 11.30 WIB (West Indonesia Time). This webinar is supported by INA-RESPOND and partners and is free of charge for all participants. Participants will receive IDI SKP and an electronic certificate*.

Registration Ended

Virtual background for INA-RESPOND 3rd Webinar: COVID-19 TreatmentDownload

CHECK and DOWNLOAD YOUR CERTIFICATE*

Download Your Certificate Here

*required attendance for the certificate is 80% of the total duration of the webinar. The certificate is gradually available 7 working days after the webinar.

Download Presentation Materials

  1. Antiviral Drugs that are Approved or Under Evaluation for the Treatment of COVID-19 – George Painter, PhD (MERCKS)
  2. Passive Immunotherapy for COVID-19 – H. Clifford Lane, MD
  3. Immunomodulators Under Evaluation for the Treatment of COVID-19 – Dr. Hiroki Saito, MPH REMAP-CAP Trial
  4. Clinical Management Summary and Guidelines (Adult) – DR. dr. Erlina Burhan, MSc, Sp.P(K)
  5. Clinical Management Summary and Guidelines (Children) – dr Yogi Prawira , Sp.A(K)
  6. Clinical Trial in Indonesia – Prof. dr. David H. Muljono, SpPD, FINASIM, PhD

Video

Screenshots

For other information and inquiries, please contact us at inaevent@ina-respond.net

Background

The coronavirus disease 2019 (COVID-19) pandemic continues to grow.  Protective vaccines have been developed, but current supplies are too low to cover worldwide demand in the coming months. Researchers worldwide are urgently looking for interventions to prevent new infections, or prevent disease progression, and lessen disease severity for those already infected. While research on new therapeutic agents for COVID-19 is key, there is also great interest in evaluating the potential of already existing medicines against COVID-19, and many clinical trials are in progress to re-purpose drugs normally indicated for other diseases. The known safety profiles shortened development timelines, and well-established markets for most of the already existing compounds proposed for COVID-19 are particularly advantageous compared to new drug discovery in a pandemic situation. This situation has inspired multiple drug repurposing screens to find antiviral therapeutics that can be rapidly used for that purpose. Biological plausibility, pathophysiological considerations, in vitro research, observational studies, and/or clinical trials with heterogeneous quality evaluated several repurposed drugs different from their current indications. To date, over 1,974 drugs and investigational drugs have been reported to have in vitro activity against SARS-CoV-2. Since almost all of these actions against human targets might be unlikely to be viable against a novel virus, the mechanism of action arises. However, some policymakers and regulatory institutions authorized emergency use of unproven COVID-19 treatments, in which the use of some of these treatments has been heavily politicized in some regions.

As of July 2021, three re-purposed anti-inflammatory drugs have shown significant survival benefits: the corticosteroid dexamethasone and the Interleukin-6 (IL-6) receptor antagonist drugs; tocilizumab, and sarilumab. Those benefits had been shown on the large studies of the Randomized, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia (REMAP-CAP) trial and the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, in which those drugs are mainly indicated to treat severe/critical COVID-19 patients to suppress inflammation that can worsen the patient’s condition. Besides the anti-inflammatory drugs, the US Food and Drug Administration (FDA) has also issued an Emergency Use Authorization (EUA) for the anti-SARS-CoV-2 monoclonal antibody (Bamlanivimab plus etesevimab, or Casirivimab plus imdevimab, or Sotrovimab) for the treatment of non-hospitalized patients with mild to moderate COVID-19 who are at high risk of progression to severe COVID-19. However, other re-purposed drugs with potential antiviral mechanisms such as hydroxychloroquine, lopinavir/ritonavir, remdesivir, and interferon-beta, have shown no significant survival benefit in two large, randomized trials despite initial reports of efficacy on in-vitro or small-scale studies. These facts show that currently, there is no single antiviral drug that has strongly proven ability to inhibit SARS-CoV-2 replication, underscoring the need for caution when interpreting early clinical trial data.

In answering those challenges, the Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is planning to conduct a webinar about COVID-19 Treatment.  INA-RESPOND is a multi-center clinical research network for infectious disease managed by the National Institute of Health Research and Development (Indonesia) in collaboration with the National Institute of Allergy and Infectious Diseases (United States) at designated Indonesian medical faculties and their teaching hospitals. As a network research organization focused on infectious disease, we also have a responsibility to provide comprehensive updates and recent evidence of COVID-19 to clinicians, researchers, and public health authorities to help tackle this disease.

Objective

The purpose of the INA-RESPOND COVID-19 Webinar is to:

  1. Provide current updates on COVID-19 treatment and trial
  2. Discuss strategies and experiences from other countries that regarded successfully controlling the COVID-19 pandemic.

Agenda

The INA-RESPOND COVID-19 Webinar is presented in 3 series. The 1st and 2nd webinar series were held on 10 April 2021 and 24 July 2021, respectively.  The 3rd webinar will be held on 4 December 2021 (Jakarta time, WIB) am / 3 December 2021 (EST) pm.

Audience

  1. National Institute of Health Research and Development (NIHRD), Ministry of Health, Indonesia
  2. INA RESPOND Study Site Team
  3. INA-RESPOND Secretariat
  4. Clinicians, Researchers, General participants

Funding

INA-RESPOND will support the funding for this Webinar. This webinar series is free of charge for all participants.

Leave a reply